Cephalosporin Drugs Market Size & Share 2026-2035

Cephalosporin Drugs Market Size

The global cephalosporin drugs market was valued at approximately USD 18.7 billion in 2025 and is projected to grow from USD 19.2 billion in 2026 to nearly USD 25.4 billion by 2035, registering a CAGR of 3.2% during the forecast period, according to the latest report published by Global Market Insights Inc.

The growth of the cephalosporin market is primarily driven by the rising global burden of bacterial infections, increasing hospitalization rates, and growing demand for broad-spectrum antibiotics.

According to the World Health Organization (WHO), lower respiratory infections remain among the leading causes of death globally, accounting for approximately 2.5 million deaths annually. In addition, the U.S. Centers for Disease Control and Prevention (CDC) estimates that more than 2.8 million antimicrobial-resistant infections occur in the U.S. each year, highlighting the continued need for effective antibacterial therapies. As cephalosporins are widely prescribed for the treatment of respiratory tract infections, urinary tract infections, skin infections, sepsis, meningitis, and surgical prophylaxis, the growing prevalence of infectious diseases continues to support market expansion.

Cephalosporins are a class of broad-spectrum beta-lactam antibiotics used to treat a wide range of bacterial infections. These antibiotics work by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death. Cephalosporins are categorized into multiple generations based on their antimicrobial spectrum and activity against gram-positive and gram-negative bacteria. First-generation cephalosporins are commonly used for skin and soft tissue infections, while later-generation cephalosporins are increasingly utilized for severe hospital-acquired infections, pneumonia, meningitis, and multidrug-resistant bacterial infections. Commonly prescribed cephalosporin drugs include ceftriaxone, cefepime, cefuroxime, cefixime, cefazolin, and ceftazidime.

Several major pharmaceutical companies are actively contributing to the expansion of the cephalosporin drugs market through product development, strategic collaborations, manufacturing expansion, and regulatory approvals. Some of the leading players operating in the market include Pfizer, Sandoz, Abbott Laboratories, Lupin Limited, Aurobindo Pharma, and Teva Pharmaceutical Industries. These companies continue to strengthen their cephalosporin portfolios through generic launches, advanced injectable antibiotic development, global distribution expansion, and investments in antimicrobial resistance-focused therapies.

The cephalosporin drugs market witnessed steady growth between 2022 and 2024, increasing from approximately USD 17.4 billion in 2022 to USD 18.2 billion in 2024. This growth can be attributed to the increasing prevalence of infectious diseases, rising antibiotic consumption in hospital and outpatient settings, growing elderly populations vulnerable to bacterial infections, and expanding use of injectable cephalosporins in critical care management. Additionally, increasing incidences of antibiotic resistance have encouraged the development and adoption of newer cephalosporin combinations with beta-lactamase inhibitors to improve efficacy against resistant pathogens. The growing availability of generic cephalosporin formulations and increasing pharmaceutical manufacturing capacity in countries such as India and China have also strengthened global market penetration.

Cephalosporin Drugs Market Trends

The cephalosporin drugs industry is witnessing steady growth driven by the increasing global burden of bacterial infections and rising demand for broad-spectrum antibiotics.

• According to the World Health Organization (WHO), lower respiratory infections remained the world’s most deadly communicable disease and ranked among the top five causes of death globally in 2021. Increasing prevalence of pneumonia, urinary tract infections, bloodstream infections, skin infections, and hospital-acquired bacterial infections is significantly supporting the demand for cephalosporin antibiotics across hospitals and outpatient settings globally.
• In addition, the rising number of surgical procedures and increasing incidence of post-operative infections are further contributing to market growth. Cephalosporins are widely used as prophylactic antibiotics before surgeries to reduce the risk of surgical site infections (SSIs). The growing volume of orthopedic, cardiovascular, gastrointestinal, and cesarean procedures worldwide continues to increase demand for injectable cephalosporin formulations in hospital settings.
• The market is also experiencing significant growth due to expanding healthcare infrastructure and improving access to antibiotics in emerging economies. Rising healthcare expenditure, increasing hospitalization rates, and improved availability of low-cost generic cephalosporins are supporting broader patient access, particularly across Asia Pacific, Latin America, and the Middle East & Africa.
• Furthermore, the growing prevalence of antimicrobial-resistant bacterial infections is driving the development and adoption of advanced-generation cephalosporins. According to WHO surveillance findings, over 40% of Escherichia coli and more than 55% of Klebsiella pneumoniae bloodstream infection isolates globally are now resistant to third-generation cephalosporins, highlighting the urgent need for newer beta-lactam/beta-lactamase inhibitor combinations and next-generation cephalosporin therapies.
• Additionally, increasing awareness regarding infection prevention and favorable government initiatives supporting infectious disease management are positively influencing the market. Several countries are strengthening hospital infection control programs, expanding reimbursement support for antibacterial therapies, and improving access to essential antibiotics, thereby supporting sustained cephalosporin demand globally.

Cephalosporin Drugs Market Analysis

Based on generation, the market is classified into first generation cephalosporins, second generation cephalosporins, third generation cephalosporins, fourth generation cephalosporins, and fifth generation cephalosporins. The third-generation cephalosporins segment dominated the market in 2025 with a revenue of USD 9.1 billion.

• The dominance of this segment is mainly due to its broad-spectrum antibacterial activity, high clinical efficacy against gram-negative infections, and widespread use in hospital-acquired infections.
• Third generation cephalosporins such as ceftriaxone, cefotaxime and ceftazidime are widely used in hospitals and critical care settings because they have good tissue penetration and a good safety profile.
• Moreover, the growing hospitalization rates worldwide and the rising prevalence of antimicrobial-resistant bacterial infections are further driving the demand for advanced cephalosporin therapies.
• In addition, the growing consumption of injectable antibiotics in inpatient care, coupled with the advancing healthcare infrastructure and accessibility to anti-infective therapies in emerging economies, will further drive the growth of this segment.
• The fifth-generation cephalosporins segment is expected to witness high growth at a CAGR of 4.9% during the forecast period owing to their strong efficacy against multidrug-resistant gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
• Increasing prevalence of antimicrobial resistance, rising demand for advanced hospital antibiotics, and growing adoption of novel beta-lactam combination therapies are further supporting the rapid growth of this segment.

 Based on application, the global cephalosporin drugs market is classified into respiratory infections, urinary tract infections (UTIs), skin and soft tissue infections, sexually transmitted infections (STIs), gastrointestinal infections, and other indications. The respiratory infections segment held the largest market share of 31.7% in 2025.

• The segment’s leading position is driven by the heavy burden of bacterial respiratory diseases, including pneumonia, bronchitis, sinusitis and other lower respiratory tract infections that require effective antibiotic treatment.
• According to the World Health Organization (WHO), lower respiratory infections are among the leading causes of death worldwide, particularly affecting children under five years and the elderly population.
• In 2019, pneumonia and other lower respiratory infections constituted the most lethal category of communicable diseases. As the fourth leading cause of death globally, they accounted for at least 2.49 million fatalities. Further, according to the WHO reports, in 2021, lower respiratory infections were the leading cause of death in low-income countries.
• Cephalosporins are widely used for community acquired and nosocomial respiratory infections because of their broad spectrum of activity, good safety profile and high activity against common respiratory pathogens.
• Furthermore, increasing air pollution, rising prevalence of smoking, rising incidence of chronic respiratory diseases and seasonal outbreaks of respiratory infections are further propelling the demand for cephalosporin-based treatments across the globe.
• On the other hand, the urinary tract infections (UTIs) segment held a market share of 25.6% in 2025 and is expected to grow at a CAGR of 3.2% over the forecast period.
• According to the National Institute of Health, in 2019, 404.6 million cases and 236,790 deaths were associated with UTIs globally. Such a high incidence of UTIs contributes to the growth of this segment.
• Further, cephalosporins, including second and third-generation, are very effective against a range of bacteria commonly associated with UTIs. These antibiotics provide broad coverage against various pathogens associated with UTI, making them suitable for empiric therapy.
• Additionally, cephalosporins are effective in treating both upper and lower UTIs. This includes infections of the bladder (cystitis) as well as infections of the kidneys (pyelonephritis). Therefore, such wide applications of cephalosporin drugs in the treatment of UTIs aid in high segmental growth.

Based on route of administration, the global cephalosporin drugs are divided into parenteral, oral, and topical. The parenteral segment dominated the market in 2025 and is expected to reach USD 13.7 billion in 2035.

• The parenteral route held the largest share in the cephalosporin drugs market in 2025, due to the heavy use of injectable cephalosporins in hospitals, intensive care units, and emergency care settings for the treatment of severe bacterial infections.
• Parenteral formulations are preferred because of their rapid onset of action, improved bioavailability and higher therapeutic effectiveness for the treatment of serious conditions such as sepsis, pneumonia, meningitis, bloodstream infections and post-surgical infections.
• In addition, the increasing hospitalization rates, growing number of surgical procedures and rising incidence of multidrug-resistant bacterial infections are significantly driving the demand for intravenous and intramuscular cephalosporin therapies.
• Furthermore, third- and fourth-generation cephalosporins, such as ceftriaxone, cefepime and ceftazidime are widely used by parenteral routes because of their broad-spectrum antibacterial activity and efficacy in critical care treatment protocols.
• The oral segment, on the other hand, was valued at USD 7.9 billion in 2025 owing to the increasing preference for convenient outpatient antibiotic therapies and the rising treatment of mild-to-moderate bacterial infections in ambulatory care settings.
• Growing availability of generic oral cephalosporins, improved patient compliance, and expanding access to primary healthcare services are further supporting segment growth globally.

Based on drug type, the global cephalosporin drugs market is bifurcated into branded and generic. The generic segment is anticipated to grow at a CAGR of 3.3% between 2026 - 2035.

• The generic drugs held the largest share of the cephalosporin drugs due to the availability of cost-effective alternatives after patent expiration of several branded cephalosporin drugs.
• The increasing demand for low-cost antibiotic regimens in hospitals, government healthcare programs, and outpatient settings has greatly accelerated the worldwide adoption of generic cephalosporins.
• Moreover, a high burden of bacterial infections, rising antibiotic consumption in emerging economies and strong presence of domestic generic pharmaceutical manufacturers are further supporting segment dominance.
• Generic cephalosporins are widely used to treat respiratory tract infections, urinary tract infections, and skin infections, as well as for surgical prophylaxis due to their proven effectiveness and low treatment costs.
• The branded drugs segment held a revenue of USD 6 billion in 2025. Branded cephalosporin drugs benefit from strong brand recognition and trust among healthcare professionals and patients. Established brands are associated with quality, safety, and efficacy, influencing prescribing practices and patient preferences.
• Further, physicians have established preferences for certain branded cephalosporin drugs based on their experiences, perceptions of efficacy, and familiarity with the brand. Thus, physician habits and prescribing patterns contribute to the sustained use of branded drugs, thereby boosting the segmental growth.

Based on distribution channel, the global cephalosporin drugs market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy segment dominated the market in 2025 with a market share of 53.7%.

• Hospitals remain the primary point of administration for injectable third-, fourth-, and fifth-generation cephalosporins used in critical care, surgical prophylaxis, sepsis management, pneumonia treatment, and intensive care unit (ICU) infections.
• In addition, increasing hospitalization rates, a growing number of surgical procedures, and rising prevalence of multidrug-resistant infections are significantly contributing to the strong demand for cephalosporin drugs through hospital pharmacies.
• The availability of advanced diagnostic facilities, physician supervision, and antimicrobial stewardship programs within hospitals further supports segment dominance.
• Moreover, expanding healthcare infrastructure and increasing investments in hospital care services across emerging economies continue to strengthen the market share of hospital pharmacies globally.

North America Cephalosporin Drugs Market

In 2025, North America held a significant share of 39.4% in the global market.

• North America, particularly the U.S., holds a leading position in the global cephalosporin drugs market owing to the high prevalence of bacterial infections, strong hospital infrastructure, and extensive utilization of broad-spectrum antibiotics in inpatient and outpatient care settings.
• The U.S. market was valued at USD 6.3 billion and USD 6.4 billion in 2022 and 2023, respectively. The market size reached approximately USD 6.7 billion in 2025, growing from USD 6.6 billion in 2024.
• The U.S. has one of the highest healthcare spending rates globally. This allows for substantial investments in pharmaceuticals, including the purchase and use of cephalosporin drugs.
• Further, the high prevalence of bacterial infections in the region contributes to the high demand for these drugs. For instance, according to the National Institutes of Health, in 2019, the total age-standardized incidence rate of respiratory tract infections in the U.S. was 339,703 per 100,000 people.
• Similarly, according to the Centers for Disease Control and Prevention (CDC), approximately 2.8 million antimicrobial-resistant infections occur annually in the U.S., resulting in more than 35,000 deaths, significantly supporting demand for advanced cephalosporin therapies.
• Additionally, rising hospitalization rates and increasing surgical procedures continue to support strong demand for injectable cephalosporins across hospitals and critical care units. According to the American Hospital Association (AHA), U.S. hospitals record over 33 million admissions annually, creating substantial demand for hospital-administered antibiotics, including third- and fourth-generation cephalosporins.
• The strong presence of major pharmaceutical companies, favorable reimbursement frameworks, and high healthcare expenditure continue to reinforce North America’s dominance in the cephalosporin drugs industry.

Europe Cephalosporin Drugs Market

Europe market accounted for a significant revenue share in 2025 and is anticipated to witness substantial growth over the forecast period.

• The market growth is primarily supported by increasing prevalence of bacterial infections, rising geriatric population, and strong adoption of hospital-based antibiotic therapies in the region.
• According to the European Centre for Disease Prevention and Control (ECDC), antimicrobial resistance causes an estimated 35,000 deaths annually across the European Economic Area (EEA), increasing the demand for effective broad-spectrum antibiotics, including advanced-generation cephalosporins.
• Additionally, the growing volume of surgical procedures and increasing incidence of healthcare-associated infections are contributing significantly to regional antibiotic consumption.
• Expanding hospital infrastructure and favorable public healthcare coverage further support widespread access to cephalosporin therapies.
• Europe also benefits from strong antimicrobial surveillance programs, increasing focus on infection prevention, and government initiatives aimed at improving antibiotic stewardship and combating antimicrobial resistance.
• Furthermore, the rising elderly population across Europe is increasing susceptibility to pneumonia, UTIs, and bloodstream infections, thereby strengthening long-term cephalosporin demand across the region.

Asia Pacific Cephalosporin Drugs Market

The Asia Pacific market is anticipated to grow at the highest CAGR during the forecast period.

• The growth is primarily attributed to the high burden of infectious diseases, rapidly expanding healthcare infrastructure, growing population base, and increasing access to antibiotic therapies across countries such as China, India, Japan, and South Korea.
• According to the World Health Organization (WHO), Asia Pacific countries continue to account for a substantial share of global infectious disease cases, particularly respiratory and gastrointestinal bacterial infections, significantly supporting antibiotic demand.
• India and China represent major growth markets owing to large patient populations, rising antibiotic consumption, and strong domestic generic pharmaceutical manufacturing capabilities.
• Furthermore, growing awareness regarding antimicrobial resistance and increasing adoption of advanced-generation cephalosporins for multidrug-resistant infections continue to support long-term market expansion throughout Asia Pacific.

Latin America Cephalosporin Drugs Market

The Latin America market is experiencing robust growth over the analysis timeframe.

• Countries such as Brazil and Mexico are witnessing increasing investments in healthcare infrastructure, hospital expansion, and infectious disease management programs, supporting growing adoption of cephalosporin antibiotics.
• Additionally, rising healthcare expenditure, improving access to generic antibiotics, and expansion of public healthcare systems are supporting broader patient access to cephalosporin therapies across Latin America.
• Brazil continues to represent one of the largest regional markets owing to its large population base and increasing hospitalization rates. Government-led initiatives aimed at strengthening infection control and antimicrobial surveillance are further contributing to market growth.

Middle East & Africa Cephalosporin Drugs Market

The Middle East & Africa (MEA) cephalosporin drugs industry is experiencing notable growth over the analysis timeframe.

• Increasing prevalence of hospital-acquired infections, respiratory infections, sepsis, and urinary tract infections is significantly contributing to the growing use of broad-spectrum cephalosporin therapies across the region.
• According to the World Bank and WHO healthcare indicators, healthcare expenditure across several Gulf Cooperation Council (GCC) countries continues to rise steadily, supporting improved access to advanced antibiotic treatments and hospital care services.
• The Middle East is also witnessing increasing surgical volumes and rising demand for perioperative antibiotic prophylaxis, which continues to drive utilization of injectable cephalosporins in hospital settings.
• Furthermore, improving healthcare access, increasing awareness regarding antimicrobial resistance, and expanding availability of generic antibiotics are expected to further strengthen market growth throughout the Middle East & Africa region.

Cephalosporin Drugs Market Share

The global cephalosporin drugs industry is highly competitive and fragmented, with competition driven by the strong presence of multinational pharmaceutical companies, regional generic manufacturers, and injectable antibiotic suppliers. Top companies including Pfizer, Abbott, Lupin, Aurobindo Pharma, and Novartis maintain strong market positions with a collective market share of ~40% through extensive portfolios of oral and injectable cephalosporin products across hospital and retail channels.

Market participants are primarily competing based on pricing, spectrum of antibacterial activity, hospital supply contracts, manufacturing scale, and regulatory approvals for advanced-generation cephalosporins. Manufacturers are increasingly focusing on the development of higher-generation cephalosporins and combination antibiotics capable of addressing multidrug-resistant bacterial infections, particularly resistant Gram-negative pathogens commonly associated with hospital-acquired infections. In addition, growing demand for sterile injectable antibiotics has encouraged companies to expand parenteral manufacturing facilities and strengthen supply chain capabilities to ensure uninterrupted hospital supply.

Cephalosporin Drugs Market Companies

A few of the prominent players operating in the cephalosporin drugs industry include:

• AbbVie
• Abbott Laboratories
• Aurobindo Pharma
• Baxter
• Cipla
• Fresenius Kabi
• GlaxoSmithKline
• Hikma Pharmaceuticals
• Lupin
• Macleods Pharmaceuticals
• Mankind Pharma
• Novartis
• Pfizer
• Shionogi
• Sun Pharmaceutical
• Teva Pharmaceutical Industries
• Zydus Lifesciences

• Pfizer

Pfizer is one of the leading players in the global cephalosporin drugs market, supported by its strong anti-infective portfolio, extensive hospital distribution network, and broad global presence. The company maintains a significant position in the market through commercialization of advanced cephalosporin and β-lactam/β-lactamase inhibitor therapies used for the treatment of severe bacterial and multidrug-resistant infections.

• AbbVie

AbbVie holds a significant position in the global cephalosporin drugs market through its portfolio of advanced anti-infective therapies targeting complicated bacterial infections and multidrug-resistant pathogens. The company’s marketed products, including ceftazidime- and ceftaroline-based therapies, support its strong presence in hospital and critical care antibiotic segments globally.

Cephalosporin Drugs Industry News:

• In April 2024, the U.S. FDA approved Basilea Pharmaceutica’s fifth-generation cephalosporin antibiotic Zevtera (ceftobiprole medocaril sodium) for the treatment of Staphylococcus aureus bloodstream infections, acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP). This approval strengthened the company’s anti-infective portfolio and expanded treatment options for multidrug-resistant bacterial infections.
• In February 2024, the U.S. FDA approved EXBLIFEP (cefepime and enmetazobactam), developed by Allecra Therapeutics, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. The approval marked the launch of a novel cephalosporin and β-lactamase inhibitor combination targeting resistant Gram-negative bacterial infections, thereby strengthening the advanced antibiotics pipeline.
• In January 2024, Venatorx Pharmaceuticals and Menarini Group entered into a commercialization agreement for cefepime-taniborbactam across 96 countries. The investigational cephalosporin combination therapy is being developed for complicated urinary tract infections and hospital-acquired bacterial pneumonia caused by multidrug-resistant pathogens.
• In October 2021, Novartis AG’s generics division Sandoz, completely acquired GlaxoSmithKline's (GSK) cephalosporin antibiotics segment. This significant transaction involved obtaining the global rights to three established brands - Zinnat, Zinacef, and Fortum, which are marketed in over 100 countries. This helped the company to increase its product portfolio.
• In February 2018, AbbVie Inc, received FDA approval for Avycaz (ceftazidime and avibactam) for the treatment of patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. This approval helped the company to widen its product portfolio, thereby contributing increased sales.

The cephalosporin drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Generation

• First generation cephalosporins
• Second generation cephalosporins
• Third generation cephalosporins
• Fourth generation cephalosporins
• Fifth generation cephalosporins

Market, By Indication

• Respiratory infections
• Urinary tract infections (UTIs)
• Skin and soft tissue infections
• Sexually transmitted infections (STIs)
• Gastrointestinal infections
• Other indications

Market, By Route of Administration

• Oral
• Parenteral
• Topical

Market, By Drug Type

• Branded
• Generic

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE